Extent of antigenic cross-reactivity among highly pathogenic H5N1 influenza viruses

Journal of Clinical Microbiology

Volumn 49, Issue 10, 2011, Pages 3531-3536

  Ducatez, Mariette F ^a   Cai, Zhipeng ^b   Peiris, Malik ^c,d   Guan, Yi ^c,d   Ye, Zhiping ^e   Wan, Xiu Feng ^b   Webby, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHANTOU UNIVERSITY   (China)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; VIRUS ANTIGEN; VIRUS SIALIDASE;

ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; AUDIOVISUAL EQUIPMENT; BLOOD ANALYSIS; CARTOGRAPHY; CHICKEN; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; HEMAGGLUTINATION INHIBITION TEST; HORSE; INFLUENZA VIRUS A H5N1; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHICKENS; CROSS REACTIONS; ERYTHROCYTES; HEMAGGLUTINATION INHIBITION TESTS; HORSES; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; NEUTRALIZATION TESTS;

AVIAN INFLUENZA VIRUS; EQUIDAE; ORTHOMYXOVIRIDAE;

EID: 80053538503     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01279-11     Document Type: Article

References (26)

1. Baras, B., et al. 2008. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3:e1401.
2. Boon, A. C., and R. J. Webby. 2009. Antigenic cross-reactivity among H5N1 viruses. Curr. Top. Microbiol. Immunol. 333:25-40.
3. Cai, Z., T. Zhang, and X. F. Wan. 2010. Concepts and applications for influenza antigenic cartography. OPTIONS VII Conference, Hong Kong, People's Republic of China.
4. Cai, Z., T. Zhang, and X. F. Wan. 2010. A computational framework for influenza antigenic cartography. PLoS Comput. Biol. 6:e1000949.
5. Carney, P. J., A. S. Lipatov, A. S. Monto, R. O. Donis, and J. Stevens. 2010. Flexible label-free quantitative assay for antibodies to influenza virus hemagglutinins. Clin. Vaccine Immunol. 17:1407-1416.
6. Chen, Y., et al. 2010. Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1. Antivir. Res. 87:81-84.
7. Chen, Y., et al. 2009. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J. Infect. Dis. 199:49-58.
8. Ducatez, M. F., et al. 2011. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc. Natl. Acad. Sci. U. S. A. 108:349-354.
9. Forrest, H. L., et al. 2009. Single- and multiple-clade influenza A H5N1 vaccines induce cross-protection in ferrets. Vaccine 27:4187-4195.
10. Galli, G., et al. 2009. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl. Acad. Sci. U. S. A. 106:7962-7967.
11. Govorkova, E. A., R. J. Webby, J. Humberd, J. P. Seiler, and R. G. Webster. 2006. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194:159-167.
12. Hoffmann, E., G. Neumann, Y. Kawaoka, G. Hobom, and R. G. Webster. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97:6108-6113.
13. Kaverin, N. V., et al. 2002. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J. Gen. Virol. 83:2497-2505.
14. Leroux-Roels, I., et al. 2008. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3:e1665.
15. Leroux-Roels, I., et al. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. (Pubitemid 47247854)
16. Luo, Q., et al. 2009. An indirect sandwich ELISA for the detection of avian influenza H5 subtype viruses using anti-hemagglutinin protein monoclonal antibody. Vet. Microbiol. 137:24-30.
17. She, R. C., E. W. Taggart, and C. A. Petti. 2010. Comparison of 10 indirect fluorescent antibodies to detect and type influenza A specimens. Arch. Pathol. Lab. Med. 134:1177-1180.
18. Song, H., et al. 2010. Induction of cross-reactive antibodies against mimotopes of H5N1 hemagglutinin. Vet. Microbiol. 145:17-22.
19. Stephenson, I., et al. 2005. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191:1210-1215.
20. Stephenson, I., J. M. Wood, K. G. Nicholson, A. Charlett, and M. C. Zambon. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 103:91-95.
21. Subbarao, K., et al. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305:192-200. (Pubitemid 36062823)
22. World Health Organization. 2011. Antigenic and genetic characteristics of influenza A(H5N1)and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. Wkly. Epidemiol. Rec. 85:418-424.
23. World Health Organization. 2011. WHO manual on animal diagnosis and surveillance. World Health Organization, Geneva, Switzerland. http: //whqlibdoc.who.int/publications/2011/9789241548090-eng.pdf.
24. Wu, W. L., et al. 2008. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J. Virol. 82:1798-1807.
25. Xie, H., et al. 2009. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice. J. Infect. Dis. 200:1874-1883.
26. Zheng, Q., et al. Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses. Antimicrob. Agents Chemother. 55:1349-1357.